Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome

被引:28
作者
Aalberts, Jan J. J. [1 ]
van Tintelen, J. Peter [2 ,3 ]
Meijboom, Lilian J. [4 ]
Polko, Annette [1 ]
Jongbloed, Jan D. H. [2 ]
van der Wal, Henriette [1 ]
Pals, Gerard [5 ]
Osinga, Jan [2 ]
Timmermans, Janneke [6 ]
de Backer, Julie [7 ]
Bakker, Marian K. [2 ]
van Veldhuisen, Dirk J. [1 ]
Hofstra, Robert M. W. [2 ]
Mulder, Barbara J. M. [4 ]
van den Berg, Maarten P. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands
[3] Durrer Ctr Cardiogenet Res, Utrecht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
[5] Free Univ Amsterdam, Med Ctr, Dept Mol Genet, Amsterdam, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, NL-6525 ED Nijmegen, Netherlands
[7] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium
关键词
FBN1-mutation; Genetics; Genotype-phenotype relation; Left ventricular dilatation; Marfan syndrome; GROWTH-FACTOR-BETA; MOLECULAR-GENETICS; TGFBR2; MUTATIONS; FBN1; IDENTIFICATION; IMPAIRMENT; DIMENSIONS; BINDING;
D O I
10.1016/j.gene.2013.10.033
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cardiovascular manifestations in patients with Marfan syndrome (MFS) are related to aortic and valvular abnormalities. However, dilatation of the left ventricle (LV) can occur, even in the absence of aortic surgery or valvular abnormalities. We evaluated genetic characteristics of patients with MFS with LV dilatation. One hundred eighty-two patients fulfilling the MFS criteria, without valvular abnormalities or previous aortic surgery, with a complete FBN1 analysis, were studied. FBN1 mutations were identified in over 81% of patients. Twenty-nine patients (16%) demonstrated LV dilatation (LV end diastolic diameter corrected for age and body surface area >112%). FBN1-positive patients carrying a non-missense mutation more often had LV dilatation than missense mutation carriers (14/74 versus 5/75; p < 0.05). Finally, FBN1-negative MFS patients significantly more often demonstrated LV dilatation than FBN1-positive patients (10/33 versus 19/149; p < 0.05). It is concluded that LV dilatation in MFS patients is more often seen in patients with a non-missense mutation and in those patients without an FBN1 mutation. Therefore physicians should be aware of the possibility of LV dilatation in these patients even in the absence of valvular pathology. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:40 / 43
页数:4
相关论文
共 30 条
  • [11] ECHOCARDIOGRAPHIC MEASUREMENTS IN NORMAL SUBJECTS FROM INFANCY TO OLD-AGE
    HENRY, WL
    GARDIN, JM
    WARE, JH
    [J]. CIRCULATION, 1980, 62 (05) : 1054 - 1061
  • [12] Latent transforming growth factor β-binding protein 1 interacts with fibrillin and is a microfibril-associated protein
    Isogai, Z
    Ono, RN
    Ushiro, S
    Keene, DR
    Chen, Y
    Mazzieri, R
    Charbonneau, NL
    Reinhardt, DP
    Rifkin, DB
    Sakai, LY
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (04) : 2750 - 2757
  • [13] Identification of a novel TGFBR2 gene mutation in a Korean patient with Loeys-Dietz aortic aneurysm syndrome;: no mutation in TGFBR2 gene in 30 patients with classic Marfan's syndrome
    Ki, CS
    Jin, DK
    Chang, SH
    Kim, JE
    Kim, JW
    Park, BK
    Choi, JH
    Park, IS
    Yoo, HW
    [J]. CLINICAL GENETICS, 2005, 68 (06) : 561 - 563
  • [14] Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome
    Kiotsekoglou, Anatoli
    Bajpai, Abhay
    Bijnens, Bart H.
    Kapetanakis, Venedictos
    Athanassopoulos, George
    Moggridge, James C.
    Mullen, Mike J.
    Nassiri, Dariush K.
    Camm, John
    Sutherland, George R.
    Child, Anne H.
    [J]. EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY, 2008, 9 (05): : 605 - 613
  • [15] Liu W, 2001, BMC Med Genet, V2, P11, DOI 10.1186/1471-2350-2-11
  • [16] The revised Ghent nosology for the Marfan syndrome
    Loeys, Bart L.
    Dietz, Harry C.
    Braverman, Alan C.
    Callewaert, Bert L.
    De Backer, Julie
    Devereux, Richard B.
    Hilhorst-Hofstee, Yvonne
    Jondeau, Guillaume
    Faivre, Laurence
    Milewicz, Dianna M.
    Pyeritz, Reed E.
    Sponseller, Paul D.
    Wordsworth, Paul
    De Paepe, Anne M.
    [J]. JOURNAL OF MEDICAL GENETICS, 2010, 47 (07) : 476 - 485
  • [17] Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome:: Identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene
    Mátyás, G
    De Paepe, A
    Halliday, D
    Boileau, C
    Pals, G
    Steinmann, B
    [J]. HUMAN MUTATION, 2002, 19 (04) : 443 - 456
  • [18] Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation
    Meijboom, LJ
    Timmermans, J
    van Tintelen, JP
    Nollen, GJ
    De Backer, J
    van den Berg, MP
    Boers, GH
    Mulder, BJM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (06) : 795 - 797
  • [19] Guidelines for the study of familial dilated cardiomyopathies
    Mestroni, L
    Maisch, B
    McKenna, WJ
    Schwartz, K
    Charron, P
    Rocco, C
    Tesson, F
    Richter, A
    Wilke, A
    Komajda, M
    [J]. EUROPEAN HEART JOURNAL, 1999, 20 (02) : 93 - 102
  • [20] Heterozygous TGFBR2 mutations in Marfan syndrome
    Mizuguchi, T
    Collod-Beroud, G
    Akiyama, T
    Abifadel, M
    Harada, N
    Morisaki, T
    Allard, D
    Varret, M
    Claustres, M
    Morisaki, H
    Ihara, M
    Kinoshita, A
    Yoshiura, K
    Junien, C
    Kajii, T
    Jondeau, G
    Ohta, T
    Kishino, T
    Furukawa, Y
    Nakamura, Y
    Niikawa, N
    Boileau, C
    Matsumoto, N
    [J]. NATURE GENETICS, 2004, 36 (08) : 855 - 860